

# Samarbejdsaftale

## 1. Parter

Mellem undertegnede

Roche Pharmaceuticals a/s

(herefter kaldet "Virksomheden")

og

medundertegnede

Brystkræftforeningen

(herefter kaldet "Organisationen")

(herefter i fællesskab benævnt "Parterne")

er der indgået følgende aftale om samarbejde.

## 2. Samarbejdsaftalens formål

Formålet med samarbejdsaftalen er, at virksomheden bestiller et review hos organisationen af en oprindeligt engelsksproget, patientrettet folder om senfølger for mennesker med brystkræft. Virksomheden vil anvende resultatet af dette review i færdiggørelsen af en dansk udgivelse af folderen.

## 3. Samarbejdsprojektets navn

Samarbejdsprojektets navn er "Review af folder om senfølger."

## 4. Parternes rolle i samarbejdet

Virksomheden forpligter sig med nærværende samarbejdsaftale til at betale organisationen for at gennemføre et review af udkast til folder.

Organisationen forpligter sig til at gennemføre reviewet og formidle sine kommentarer til virksomheden, inkl. at producere 2 – 3 citater fra mennesker med brystkræft, som kan indgå i en dansk version af folderen.

## **5. Tidsramme**

Samarbejdet, hvis nærmere formål og omfang er beskrevet i pkt. 2 og 4, skal afvikles fra underskrivelse af samarbejdsaftalen og indtil 17. januar 2025.

Parternes rettigheder og forpligtelser i henhold til nærværende samarbejdsaftale løber fra underskriftsdato og indtil samarbejdsaftalens forpligtelser er opfyldt, medmindre andet udtrykkeligt er aftalt.

## **6. Finansiell ydelse**

10.000 kr. excl. moms.

## **7. Ikke-finansiell ydelse**

Ej relevant.

## **8. Offentliggørelse**

Nærværende samarbejdsaftale er offentligt tilgængelig på Virksomhedens hjemmeside [www.roche.dk](http://www.roche.dk) frem til 17. januar 2027.

Jf. Etisk Nævn for Lægemiddelvirksomheders vejledning til ”Etiske regler for lægemiddelindustriens samarbejde med patientforeninger mv.” skal det understreges, at patientforeninger på sin hjemmeside skal offentliggøre alle økonomiske fordele, herunder økonomiske sponsorater (pengebeløb) og naturalier, som foreningen har modtaget fra lægemiddelvirksomheder, jf. reklamebekendtgørelsens § 21. Offentliggørelsen skal ske på en sådan måde, at størrelsen af økonomiske fordele fra hver enkelt virksomhed fremgår af hjemmesiden. Oplysningerne skal gøres tilgængelige på hjemmesiden senest én måned efter, at patientforeningen har modtaget den økonomiske fordel. Oplysningerne skal være tilgængelige på hjemmesiden i mindst to år.

## **9. Anvendelse af Organisationens navn**

Organisationen accepterer, at Virksomheden anvender Organisationens navn i forbindelse med samarbejdet på Virksomhedens hjemmeside [www.roche.dk](http://www.roche.dk).

## **10. Uafhængighed og habilitet**

Parterne erklærer ved sin underskrift, at det står Organisationens frit at samarbejde med flere lægemiddelvirksomheder, ligesom Virksomheden har mulighed for at samarbejde med en eller flere organisationer. Parterne erklærer samtidig, at der ikke i samarbejdet stilles krav om eneret i forhold til konkrete produkt- eller terapiområder.

Virksomheden erklærer ved sin underskrift af nærværende samarbejdsaftale ikke at stille betingelser for organisationens faglige og interessepolitiske standpunkter.

Virksomheden erklærer ved sin underskrift ikke at have et tillidshverv i Organisationens, der har betydning for nærværende samarbejdsaftale.

## **11. Misligholdelse**

Såfremt en af Parterne misligholder sine forpligtelser i henhold til nærværende samarbejdsaftale, kan den ikke misligholdende part ophæve samarbejdsaftalen med øjeblikkelig virkning. Den ikke misligholdende part er i øvrigt berettiget til at bringe andre efter dansk ret til rådighed stående misligholdelsesbeføjelser til anvendelse, herunder retten til at kræve erstatning, uanset om aftalen ophæves.

## **12. Lovvalg**

Nærværende samarbejdsaftale er i enhver henseende underlagt dansk ret.

## **13. Konfliktløsning**

Såfremt tvister ikke kan bilægges igennem mægling, skal disse indbringes for Sø- og Handelsretten i København.

## 14. Underskrift

København, 18 December 2024

DocuSigned by:



90D513A8912C4A8...  
Anja Skjoldborg Hansen

*Formand, Brystkræftforeningen*

København, 18 December 2024

Signed by:



91A12969174A416...  
Poul Riese

*Patient Partnership Lead,*

*Roche Pharmaceuticals a/s*

Signed by:



6E287418733647E...  
Pia Møllgaard Mikkelsen,

*Business Lead*

*Roche Pharmaceuticals a/s*

## Certificate Of Completion

Envelope Id: DC6045EE-085F-4329-BC0C-EB7F4823A939  
 Subject: Complete with Docusign: Aftale om køb af review hos BF.pdf  
 Source Envelope:  
 Document Pages: 4  
 Certificate Pages: 4  
 AutoNav: Enabled  
 Envelopeld Stamping: Disabled  
 Time Zone: (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna

Status: Completed

Envelope Originator:  
 Karin Fryland  
 Grenzacherstrasse 124  
 Basel, Basel-Stadt 4070  
 karin.fryland@roche.com  
 IP Address: 196.3.50.247

## Record Tracking

Status: Original  
 12/18/2024 9:23:06 AM

Holder: Karin Fryland  
 karin.fryland@roche.com

Location: DocuSign

## Signer Events

Poul Riese  
 poul.riese@roche.com  
 Security Level: Email, Account Authentication  
 (None)

## Signature

Signed by:  
  
 91A12969174A416...

Sent: 12/18/2024 9:30:40 AM  
 Viewed: 12/18/2024 11:40:45 AM  
 Signed: 12/18/2024 11:41:01 AM

Signature Adoption: Pre-selected Style  
 Using IP Address: 62.198.134.8

## Electronic Record and Signature Disclosure:

Accepted: 12/18/2024 11:40:45 AM  
 ID: fcad4447-659d-44ed-815c-97533eb68a0a  
 Company Name: F. Hoffmann-La Roche Ltd

Pia Møllgaard Mikkelsen  
 pia.mollgaard@roche.com  
 Security Level: Email, Account Authentication  
 (None)

Signed by:  
  
 6E287418733647E...


Sent: 12/18/2024 11:41:02 AM  
 Viewed: 12/18/2024 11:57:46 AM  
 Signed: 12/18/2024 11:58:33 AM

Signature Adoption: Pre-selected Style  
 Using IP Address: 62.198.224.207

## Electronic Record and Signature Disclosure:

Accepted: 12/18/2024 11:57:46 AM  
 ID: 0d028e11-04f6-4f21-a90b-faf232412a58  
 Company Name: F. Hoffmann-La Roche Ltd

Anja Skjoldborg Hansen  
 ansk@brystkraeft.dk  
 President of the board  
 Security Level: Email, Account Authentication  
 (None)

DocuSigned by:  
  
 90DB13A8013C4A8...

Sent: 12/18/2024 11:58:34 AM  
 Viewed: 12/18/2024 12:03:58 PM  
 Signed: 12/18/2024 12:04:08 PM

Signature Adoption: Drawn on Device  
 Using IP Address: 130.225.0.251

## Electronic Record and Signature Disclosure:

Accepted: 5/24/2024 12:56:17 PM  
 ID: adc52752-9a62-4b36-8b8a-877bf873ba1b  
 Company Name: F. Hoffmann-La Roche Ltd

## In Person Signer Events

## Signature

## Timestamp

## Editor Delivery Events

## Status

## Timestamp

## Agent Delivery Events

## Status

## Timestamp

## Intermediary Delivery Events

## Status

## Timestamp

<b>Certified Delivery Events</b>	<b>Status</b>	<b>Timestamp</b>
----------------------------------	---------------	------------------

<b>Carbon Copy Events</b>	<b>Status</b>	<b>Timestamp</b>
---------------------------	---------------	------------------

<b>Witness Events</b>	<b>Signature</b>	<b>Timestamp</b>
-----------------------	------------------	------------------

<b>Notary Events</b>	<b>Signature</b>	<b>Timestamp</b>
----------------------	------------------	------------------

<b>Envelope Summary Events</b>	<b>Status</b>	<b>Timestamps</b>
--------------------------------	---------------	-------------------

Envelope Sent	Hashed/Encrypted	12/18/2024 9:30:40 AM
Certified Delivered	Security Checked	12/18/2024 12:03:58 PM
Signing Complete	Security Checked	12/18/2024 12:04:08 PM
Completed	Security Checked	12/18/2024 12:04:08 PM

<b>Payment Events</b>	<b>Status</b>	<b>Timestamps</b>
-----------------------	---------------	-------------------

<b>Electronic Record and Signature Disclosure</b>
---

# **Guidelines for the use of the DocuSign electronic signing system within F. Hoffmann-La Roche and companies of the Roche Group**

## **LEGAL DISCLOSURE**

By placing my electronic signature on this document, I expressly consent to use and rely on Electronic and Digital Signatures and I understand my signature will have the same binding effect as if I was providing a handwritten signature.

I also confirm the email address that I am using as a valid one to be notified and identified electronically, for example through the DocuSign System, and/or to identify me as the signer of the document. I should inform Roche in the case that the email address changes.

## **CONSUMER DISCLOSURE**

From time to time, F. Hoffmann-La Roche and companies of the Roche Group (hereinafter referred to as we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign, Inc. (DocuSign) electronic signing system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your consent by clicking the 'I agree' button at the bottom of this document.

### **Consequences of changing your mind**

To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of a DocuSign envelope instead of signing it. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

### **How to contact us**

You may contact us to let us know of your changes as to how we may contact you electronically, to request certain information from us and to withdraw your prior consent to receive notices and disclosures electronically. To do so contact the sender of the envelope.

### **To advise us of your new email address**

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to the sender of the envelope and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address. In addition, you must notify DocuSign, Inc. to arrange for your new email address to be reflected in your DocuSign account by following the process for changing email in the DocuSign system.

### **To withdraw your consent**

To inform us that you no longer want to receive future notices and disclosures in electronic format you may decline to sign a document from within your DocuSign session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent.

### **Acknowledging your access and consent to receive materials electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to email this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC CONSUMER DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify the account owner as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by the account owner during the course of my relationship with you.
- I acknowledge the information included in the† [DocuSign Privacy Policy](#)